PVC Individual Case Safety Reports 2 — Questions and Answers
Question 1: Which field in an ICSR is used to capture the outcome of the adverse event at the time of reporting?
- Patient medical history
- Reaction outcome (Correct answer)
- Drug indication
- Reporter qualification
Correct answer: Reaction outcome
The reaction outcome field documents whether the patient recovered, is recovering, had sequelae, died, or the outcome is unknown at the time of the report.
Question 2: Under FDA regulations, what is the expedited reporting timeframe for a serious, unexpected, and drug-related adverse event from a clinical trial?
- 7 calendar days
- 15 calendar days (Correct answer)
- 30 calendar days
- 60 calendar days
Correct answer: 15 calendar days
FDA requires IND safety reports for serious, unexpected adverse drug reactions to be submitted within 15 calendar days of first receiving the information.
Question 3: What distinguishes a 'follow-up' ICSR from an 'initial' ICSR?
- It is filed by a different reporter
- It contains new or updated information on a previously reported case (Correct answer)
- It is always submitted within 7 days
- It only covers fatal outcomes
Correct answer: It contains new or updated information on a previously reported case
A follow-up ICSR provides additional or corrected information for a case that has already been reported, linked by the same case identifier.
Question 4: Which organization maintains the E2B(R3) standard for electronic ICSR transmission?
- WHO
- ICH (Correct answer)
- FDA
- EMA
Correct answer: ICH
The International Council for Harmonisation (ICH) developed and maintains the E2B guideline specifying the data elements and format for electronic transmission of ICSRs.
Question 5: A spontaneous report received from a healthcare professional describes a patient who experienced anaphylaxis after taking a marketed drug. How should this case be assessed for seriousness?
- Not serious, because anaphylaxis is a known drug reaction
- Serious, because it is life-threatening (Correct answer)
- Serious only if the patient was hospitalized
- Not serious if the patient recovered fully
Correct answer: Serious, because it is life-threatening
Anaphylaxis meets the ICH E2A seriousness criterion of 'life-threatening,' making it a serious adverse event regardless of the outcome.
Question 6: What is the minimum dataset required to consider a spontaneous adverse event report a 'valid' ICSR?
- Reporter, patient initials, suspect drug, adverse event (Correct answer)
- Reporter, patient name, dose, country
- Suspect drug, lot number, adverse event, outcome
- Patient, physician, drug, regulatory submission date
Correct answer: Reporter, patient initials, suspect drug, adverse event
ICH E2D defines the four minimum elements for a valid ICSR: an identifiable reporter, an identifiable patient, a suspect drug, and at least one adverse event.
Question 7: Which narrative section of an ICSR summarizes the clinical course of the adverse event and is required in E2B(R3) submissions?
- G.k.9 – Drug-reaction interval
- H.1 – Case narrative (Correct answer)
- E.i.1 – Reaction description
- B.1.1 – Patient age
Correct answer: H.1 – Case narrative
The H.1 field in E2B(R3) contains the case narrative, which provides a free-text summary of the clinical course, relevant medical history, and assessment.
PVC Individual Case Safety Reports 2
Which field in an ICSR is used to capture the outcome of the adverse event at the time of reporting?